HCPCS Level II code J1438 identifies a 25 mg injection of etanercept administered under physician supervision and not intended for patient self-administration. This designation matters nationally because it distinguishes clinic- or office-administered biologic therapy from self-injectable drug claims, affecting billing pathways, site-of-service classification, and Medicare coverage rules. The code is commonly encountered in rheumatology and dermatology practices that provide parenteral biologic treatments.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1438 represents clinically and operationally, plus guidance on typical sites of service and service type. The publication summarizes relevant benchmarks, payer coverage patterns, and recent policy considerations that influence how payers process physician-administered biologic injections. It also provides clinical context about etanercept as a parenteral biologic and practical implications for coding and claims workflows.

Where input data was not provided, the report notes those fields as unavailable and focuses on the available national-level coding and service information.